Chemotherapy‐driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia
British Journal of Haematology · 2026-05 · 208 (5) · 1572-1583
DOI: 10.1111/bjh.70431 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 17.03.2026. Verfasst von Foteini Kalampalika und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Mesenchymal Stem Cells, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Wnt Signaling Pathway. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Society of Hematology, Global Research Award, Kay Kendall Leukaemia Fund, Barts Charity.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Despite recent advances, treatment outcomes for adults with acute lymphoblastic leukaemia (ALL) remain poor. Although patients often exhibit an initial favourable response to chemotherapy, with substantial clearance of tumour cells, most patients eventually relapse. This indicates the persistence of a chemoresistant ALL subpopulation capable of driving disease regeneration. Growing evidence implicates interactions between leukaemia cells and the bone marrow (BM) niche in this process. Our findings show that BM‐derived mesenchymal stem cells (MSCs) and adipocytes (BMAds) promote chemotherapy resistance in ALL cells via activation of the wingless‐related integration site (WNT) signalling pathway. Chemotherapy‐treated co‐cultures of MSCs/BMAds and ALL cells exhibited upregulation of several WNT ligands in the stromal compartment. Notably, pharmacological inhibition of WNT signalling abrogated the stromal‐mediated chemoprotection and enhanced ALL cell apoptosis in vitro. In vivo, WNT inhibition in a p185 BCR‐ABL Arf −/− B‐ALL mouse model sensitised leukaemia cells to chemotherapy, delaying relapse and extending survival. Collectively, these results support the therapeutic potential of WNT inhibitors as a strategy to block the cross‐talk between the BM stroma and leukaemic cells and reduce ALL chemoresistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
ORCID-Profile: Miguel Ganuza
Förderung
- American Society of Hematology, Global Research Award
- Kay Kendall Leukaemia Fund
- Barts Charity
- The Greg Wolf Fund
- Leukaemia UK (John Goldman Fellowship)
- Medical Research Council (MRC Career Development Award)
- Gabrielle's Angels Foundation
- Blood Cancer UK
Zitieren
APA
Kalampalika, F., Jiménez-Pompa, A., Sánchez-Lanzas, R., Patel, B., & Ganuza, M. (2026). Chemotherapy‐driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia. British Journal of Haematology, 208(5), 1572-1583. https://doi.org/10.1111/bjh.70431
Vancouver
Kalampalika F, Jiménez-Pompa A, Sánchez-Lanzas R, Patel B, Ganuza M. Chemotherapy‐driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia. British Journal of Haematology. 2026;208(5):1572-1583. doi:10.1111/bjh.70431
BibTeX
@article{Kalampalika2026,
author = {Kalampalika, Foteini and Jiménez-Pompa, Amanda and Sánchez-Lanzas, Raúl and Patel, Bela and Ganuza, Miguel},
title = {Chemotherapy‐driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia},
journal = {British Journal of Haematology},
year = {2026},
volume = {208},
number = {5},
pages = {1572--1583},
doi = {10.1111/bjh.70431}
}
EUVIMED